Synthesis of new 3-arylisoquinolinamines: Effect on topoisomerase I inhibition and cytotoxicity

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 24, 2003, Pages 4451-4454

  Cho, Won Jea ^a   Min, Sun Young ^a   Le, Thanh Nguyen ^a   Kim, Tae Sung ^a  

^a Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CWJ A 5; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; ISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYMATIC ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LUNG ADENOCARCINOMA; MELANOMA CELL; OVARY CANCER; STRUCTURE ACTIVITY RELATION;

EID: 0345358468     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.001     Document Type: Article

References (19)

1. (a) Wang J.C. Annu. Rev. Biochem. 65:1996;635 (b) Liu L.F. Annu. Rev. Biochem. 58:1989;351.
2. Chen A.Y., Liu L.F. Annu. Rev. Pharmacol. Toxicol. 34:1994;191.
3. Pommier Y., Pourquier P., Fan Y., Strumberg D. Biochim. Biophys. Acta. 1400:1998;83.
4. Rajendra R., Gounder M.K., Saleem A., Schellens J.H.M., Ross D.D., Bates S.E., Sinko P., Rubin E.H. Cancer Res. 63:2003;3228. and references cited therein.
5. (a) Makhey D., Gatto B., Yu C., Liu A., Liu L.F., LaVoie E. J. Med. Chem. Res. 5:1995;1 (b) Janin Y.L., Croisy A., Rious J.-L., Bisagni E. J. Med. Chem. 36:1993;3686 (c) Singh S.K., Ruchelman A.L., Li T.-K., Liu A., Liu L.F., LaVoie E.J. J. Med. Chem. 46:2003;2254.
6. (a) Jayaraman M., Fox B.M., Hollingshead M., Kohlhagen G., Pommier Y., Cushman M. J. Med. Chem. 45:2002;242 (b) Fox B.M., Xiao X., Antony S., Kohlhagen G., Pommier Y., Staker L.S., Cushman M. J. Med. Chem. 46:2003;3275.
7. Yamashita Y., Fujii N., Murakaya C., Ashizawa T., Okabe M., Nakano H. Biochemistry. 31:1992;12069.
8. Yamashita Y., Kawada S., Fujii N., Nakano H. Biochemistry. 30:1991;5838.
9. Vicker N., Burgess L., Chuckowree I.S., Dodd R., Fokes A.J., Hardick D., Hancox T.C., Miller W., Milton J., Sohal S., Wang S., Wren S.P., Charlton P.A., Dangerfield W., Liddle C., Mistry P., Stewart A.J., Denny W.A. J. Med. Chem. 45:2002;721.
10. Redinbo M.R., Stewart L., Kuhn P., Champoux J.J., Hol W.G.J. Science. 279:1998;1504.
11. Staker B.L., Hjerrild K., Feese M.D., Behnke C.A., Burgin A.B. Jr., Stewart L. Proc. Natl. Acad. Sci. U.S.A. 99:2002;15387.
12. Cho W.-J., Kim E.-K., Park I.Y., Jeong E.Y., Kim T.S., Le T.N., Kim D.-D., Lee E.-S. Bioorg. Med. Chem. 10:2002;2953.
13. Cho W.-J., Park M.-J., Chung B.-H., Lee C.-O. Bioorg. Med. Chem. Lett. 8:1998;41.
14. Kim K.E., Cho W.-J., Chang S.J., Yong C.S., Lee C.H., Kim D.D. Int. J. Pharm. 217:2001;101.
15. (a) Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., Scudiero D.A., Monks A., Boyd M.R. J. Natl. Cancer Inst. 82: 1990;1113 (b) Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. J. Natl. Cancer Inst. 82:1990;1107.
16. Fukuda M., Nishio K., Kanzawa F., Ogasawara H., Ishida T., Arioka H., Bojanowski K., Oka M., Saijo N. Cancer Res. 576:1996;789.
17. The Sybyl program (Version 6.7) was supplied by Tripos Associates, 1699 South Hanley Road, Suite 303, St. Louis, MO 63144, USA.
18. Kim H.-S., Lee T.-B., Choi C.-H. Biochem. Biophys. Res. Commun. 281:2001;109.
19. 500 ng supercoiled pBR 322 DNA was incubated with 1 unit topoisomerase I in the absence or presence of camptothecin or the compounds for 30 min at 37 °C. The reaction mixtures were analyzed on 1% agarose gel followed by ethidium bromide staining.